InsidersTradesSigma
UCB: insider trades · Belgium · FSMA
FSMA:ucbBE0003739530BE·FSMAMcap 45.1Bn€Healthcare & Pharma
Discover the full directors' dealings record of UCB, a publicly traded company based in Belgium. Shares are listed on BE BE, under the authority of FSMA. Operating in the Healthcare & Pharma sector, UCB has logged 50 public disclosures. Market capitalisation: €45.1bn. The latest transaction was filed on 13 April 2026 — Sale. Among the most active insiders: Caeymaex Emmanuel. All data is openly available.
50
Insider Decl.
0
Thresholds
€4m
35 ops.
Buy Volume
€18m
14 ops.
Sell Volume
Financial data
237.00 €
Analyst consensus
19 analystsBuy
195.00 €Target 288.21 €(+22%)340.00 €
Valuation
PER (trailing)29.5x
PER (forward)17.4x
P/Book4.2x
Beta0.17
Balance sheet & cash
Market cap45.12 Bn€
Debt / Equity21%
Profitability & ownership
ROE14.9%
ROA7.0%
% insiders36.3%
% institutions39.8%
Last declaration on 13 April 2026
Declarations50 total
Executives●Sale10FSMA
€835,4253,084 shares@ €270.890.0019% mcap22.3% of flow
ShareEuronext Brussels
FSMA:ucb-126·
Executives●Purchase9FSMA
€809,8917,937 shares@ €102.040.0018% mcap11.2% of flow
ShareOff exchange
FSMA:ucb-86·
Ideal exit: 3 Jan 2027 (T+270)
Executives●Sale8FSMA
€274,5181,010 shares@ €271.800.0006% mcap3.8% of flow
ShareEuronext Brussels
FSMA:ucb-62·
Executives●Sale11FSMA
€2m7,937 shares@ €266.700.0047% mcap29.4% of flow
ShareEuronext Brussels
FSMA:ucb-33·
Executives●Purchase8FSMA
04,031 shares0
Options /warrants for employees or managersOff exchange
FSMA:ucb-129·
Ideal exit: 2 Jan 2027 (T+270)
Executives●Purchase8FSMA
021,643 shares0
ShareOff exchange
FSMA:ucb-68·
Ideal exit: 27 Dec 2026 (T+270)
Executives●Purchase8FSMA
0780 shares0
ShareOff exchange
FSMA:ucb-26·
Ideal exit: 27 Dec 2026 (T+270)
Executives●Purchase8FSMA
03,823 shares0
Options /warrants for employees or managersOff exchange
FSMA:ucb-46·
Ideal exit: 28 Dec 2026 (T+270)
Executives●Purchase8FSMA
05,802 shares0
Options /warrants for employees or managersOff exchange
FSMA:ucb-24·
Ideal exit: 28 Dec 2026 (T+270)
Executives●Purchase8FSMA
02,464 shares0
Options /warrants for employees or managersOff exchange
FSMA:ucb-190·
Ideal exit: 28 Dec 2026 (T+270)
Executives●Purchase8FSMA
03,489 shares0
Options /warrants for employees or managersOff exchange
FSMA:ucb-76·
Ideal exit: 29 Dec 2026 (T+270)
Executives●Purchase8FSMA
04,043 shares0
ShareOff exchange
FSMA:ucb-1·
Ideal exit: 27 Dec 2026 (T+270)
Executives●Purchase8FSMA
03,528 shares0
ShareOff exchange
FSMA:ucb-60·
Ideal exit: 27 Dec 2026 (T+270)
Executives●Purchase8FSMA
02,549 shares0
Options /warrants for employees or managersOff exchange
FSMA:ucb-18·
Ideal exit: 27 Dec 2026 (T+270)
Executives●Purchase8FSMA
03,084 shares0
ShareOff exchange
FSMA:ucb-225·
Ideal exit: 27 Dec 2026 (T+270)
Executives●Purchase8FSMA
011,542 shares0
Options /warrants for employees or managersOff exchange
FSMA:ucb-116·
Ideal exit: 27 Dec 2026 (T+270)
Executives●Purchase8FSMA
02,787 shares0
ShareOff exchange
FSMA:ucb-178·
Ideal exit: 27 Dec 2026 (T+270)
Executives●Purchase8FSMA
03,873 shares0
ShareOff exchange
FSMA:ucb-108·
Ideal exit: 27 Dec 2026 (T+270)
Executives●Purchase20FSMA
€127,745500 shares@ €255.490.0003% mcap100.0% of flow
ShareOff exchange
FSMA:ucb-107·
Ideal exit: 4 Oct 2026 (T+270)
Executives●Purchase8FSMA
€239,9703,000 shares@ €79.990.0005% mcap3.3% of flow
ShareOff exchange
FSMA:ucb-187·
Ideal exit: 5 Oct 2026 (T+270)
Executives●Sale9FSMA
€762,8133,000 shares@ €254.270.0017% mcap10.6% of flow
ShareEuronext Brussels
FSMA:ucb-198·
Executives●Purchase8FSMA
€73,619966 shares@ €76.210.0002% mcap1.0% of flow
ShareOff exchange
FSMA:ucb-179·
Ideal exit: 15 Sept 2026 (T+270)
Executives●Sale8FSMA
€230,391966 shares@ €238.500.0005% mcap3.2% of flow
ShareEuronext Brussels
FSMA:ucb-226·
Executives●Sale9FSMA
€714,9003,000 shares@ €238.300.0016% mcap9.9% of flow
ShareEuronext Brussels
FSMA:ucb-112·
Executives●Purchase8FSMA
€239,9703,000 shares@ €79.990.0005% mcap3.3% of flow
ShareOff exchange
FSMA:ucb-191·
Ideal exit: 15 Sept 2026 (T+270)
25 of 50 declarations
About UCB
UCB is a Belgian biopharmaceutical company focused on developing medicines for severe diseases. It is listed on the Brussels stock market (XBRU).
